RE: RE-ALL THE BEST FOR 20224 Jan 2022 18:10
crispiano it should reflect on SP. there is more of an appetite for tech stocks/ med tech stocks on the nasdaq, there is also more avenues for fundraising which should grow the company faster. Also a wider investment market where across the pond where the US investors struggle to buy shares in AGL without going through the off market (OTC/pink sheet)
you could agrue that there is a better chance of partnerships and mergers/buyouts if already listed on nasdaq where the merger/buyout is from a US listed company. all the big pharma money is from nasdaq listed companies.
while listed on the aim market it may hold back growth, i believe the nasdaq would open a lot more doors and quicker to justify a higher SP
so in short answer is a reflection on SP which should be higher